The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments wanes and Donald Trump’s tariff and price-cut threats weigh on the ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

An official report on August 14, 2025 reveals Representative Scott Franklin's recent purchase of Novo Nordisk NVO +1.75% Get Free Report stock, valued between $18,004 and $95,000. The transaction took ...

Novo Nordisk NVO recently underwent a major leadership transition, as Lars Fruergaard Jørgensen stepped down as CEO on Aug. 7 ...

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...

With the rise of major festivals such as Vodun Days and the Porto-Novo Mask Festival, Benin is leveraging the heritage of ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...

Computational research in fruit flies revealed how spontaneously arising genes are tightly controlled, offering insights into ...